journal
MENU ▼
Read by QxMD icon Read
search

Drugs

journal
https://www.readbyqxmd.com/read/30022383/targeting-gastrointestinal-transport-proteins-to-control-hyperphosphatemia-in-chronic-kidney-disease
#1
Denis Fouque, Marc Vervloet, Markus Ketteler
Management of hyperphosphatemia in patients with dialysis-dependent chronic kidney disease remains a major challenge, requiring a multifaceted approach that includes dietary phosphate restriction, dialysis, and phosphate binders. However, these treatments fail to meet serum phosphate targets in many patients, potentially further exacerbating the significant morbidity and mortality burden associated with the disease. Recent advances in our understanding of the mechanisms underlying phosphate homeostasis have shed new light on the issue and suggest that gastrointestinal transport proteins may be promising targets for new hyperphosphatemia treatments...
July 18, 2018: Drugs
https://www.readbyqxmd.com/read/30014268/centrally-acting-agents-for-obesity-past-present-and-future
#2
REVIEW
Ann A Coulter, Candida J Rebello, Frank L Greenway
For many years, obesity was believed to be a condition of overeating that could be resolved through counseling and short-term drug treatment. Obesity was not recognized as a chronic disease until 1985 by the scientific community, and 2013 by the medical community. Pharmacotherapy for obesity has advanced remarkably since the first class of drugs, amphetamines, were approved for short-term use. Most amphetamines were removed from the obesity market due to adverse events and potential for addiction, and it became apparent that obesity pharmacotherapies were needed that could safely be administered over the long term...
July 16, 2018: Drugs
https://www.readbyqxmd.com/read/30003467/correction-to-nonacog-beta-pegol-a-review-in-haemophilia-b
#3
Yahiya Y Syed
The article Nonacog Beta Pegol: A Review in Haemophilia B, written by Yahiya Y. Syed, was originally published Online First without open access. After publication in volume 77, issue 18, pages 2003-2012 Novo Nordisk A/S requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Novo Nordisk A/S. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons...
July 13, 2018: Drugs
https://www.readbyqxmd.com/read/30003466/assessment-of-the-risk-of-rhabdomyolysis-and-myopathy-during-concomitant-treatment-with-ticagrelor-and-statins
#4
REVIEW
Dorota Danielak, Marta Karaźniewicz-Łada, Franciszek Główka
The introduction of ticagrelor, one of the first directly-acting oral antiplatelet drugs, provided new possibilities in the prevention of thrombotic events in patients with acute coronary syndromes (ACS). Current guidelines recommend ticagrelor in dual antiplatelet therapy with aspirin over clopidogrel for prevention of stent thrombosis in patients with ACS. Moreover, in the management of ACS, lipid-lowering treatment with high-intensity statin therapy is advised for secondary prevention of cardiovascular events over the long term...
July 12, 2018: Drugs
https://www.readbyqxmd.com/read/29995177/avatrombopag-first-global-approval
#5
Matt Shirley
Avatrombopag (Doptelet® ) is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders. In May 2018 avatrombopag received its first global approval, in the USA, for use in the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. A Marketing Authorization Application for use of avatrombopag in this indication was submitted to the EMA in April 2018...
July 11, 2018: Drugs
https://www.readbyqxmd.com/read/29968152/the-future-of-il-1-targeting-in-kidney-disease
#6
Baris Afsar, Adrian Covic, Alberto Ortiz, Rengin Elsurer Afsar, Mehmet Kanbay
Interleukin (IL)-1α and IL-1β are proinflammatory cytokines that play a role in many diseases such as rheumatoid arthritis, juvenile rheumatoid arthritis, gout, and periodic inflammatory syndromes, including familial Mediterranean fever and Muckle-Wells syndrome. Drugs targeting IL-1 such as recombinant IL-1Ra (anakinra), neutralizing anti-IL-1β antibodies (canakinumab) and IL-1β traps (rilonacept) are in clinical use to treat these diseases. Additionally, experimental evidence suggests a role of IL-1 in kidney disease and hypertension and targeting IL-1 showed promising results in high cardiovascular risk patients, hemodialysis and renal transplantation patients...
July 2, 2018: Drugs
https://www.readbyqxmd.com/read/29968151/erenumab-first-global-approval
#7
Anthony Markham
Amgen and Novartis are developing erenumab (AIMOVIG™, erenumab-aooe)-a fully human monoclonal antibody calcitonin gene-related peptide (CGRP) receptor antagonist-for the prevention of migraine. CGRP is a vasodilatory neuropeptide implicated in the pathophysiology of migraine and treatment with erenumab was associated with significant reductions in migraine frequency in phase II and III clinical trials. Based on these positive results erenumab was recently approved in the US for the preventive treatment of migraine in adults and has received a positive opinion in the EU for the prophylaxis of migraines in adults who have at least 4 migraine days per month...
July 2, 2018: Drugs
https://www.readbyqxmd.com/read/29961185/new-developments-in-the-management-of-cytomegalovirus-infection-after-transplantation
#8
REVIEW
Atibordee Meesing, Raymund R Razonable
Cytomegalovirus (CMV) continues to be one of the most important pathogens that universally affect solid organ and allogeneic hematopoietic stem cell transplant recipients. Lack of effective CMV-specific immunity is the common factor that predisposes to the risk of CMV reactivation and clinical disease after transplantation. Antiviral drugs are the cornerstone for prevention and treatment of CMV infection and disease. Over the years, the CMV DNA polymerase inhibitor, ganciclovir (and valganciclovir), have served as the backbone for management, while foscarnet and cidofovir are reserved for the management of CMV infection that is refractory or resistant to ganciclovir treatment...
June 30, 2018: Drugs
https://www.readbyqxmd.com/read/29943376/the-significance-of-the-intestinal-microbiome-for-vaccinology-from-correlations-to-therapeutic-applications
#9
Vanessa C Harris
Despite unprecedented advances in understanding the intestinal microbiome, its potential to improve fields such as vaccinology has yet to be realized. This review briefly outlines the immunologic potential of the intestinal microbiome for vaccinology and highlights areas where the microbiome holds specific promise in vaccinology. Oral rotavirus vaccine effectiveness in low-income countries is used as a case study to describe how the intestinal microbiome may be employed to improve a vaccine's immunogenicity...
June 26, 2018: Drugs
https://www.readbyqxmd.com/read/29943375/regorafenib-a-review-in-metastatic-colorectal-cancer
#10
Sohita Dhillon
Regorafenib (Stivarga® ) is an oral small-molecule multiple kinase inhibitor. It is indicated worldwide for patients with metastatic colorectal cancer (mCRC). In the EU and USA it is indicated for patients with mCRC who have been previously treated with, or are not considered candidates for available therapies, including fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and, if RAS wild-type, an anti-EGFR therapy. In Japan, it is indicated for the treatment of unresectable, advanced/recurrent CRC. The addition of regorafenib to best supportive care prolonged median overall survival (OS; by up to 2...
June 26, 2018: Drugs
https://www.readbyqxmd.com/read/29926311/andexanet-alfa-first-global-approval
#11
Young-A Heo
Intravenous andexanet alfa [coagulation factor Xa (recombinant), inactivated-zhzo; Andexxa® ] is a first-in-class recombinant modified factor Xa protein that has been developed by Portola Pharmaceuticals as a universal antidote to reverse anticoagulant effects of direct or indirect factor Xa inhibitors. In May 2018, andexanet alfa received its first global approval in the USA for use in patients treated with rivaroxaban and apixaban, when reversal of anticoagulant effects is required in life-threatening or uncontrolled bleeding...
June 20, 2018: Drugs
https://www.readbyqxmd.com/read/29923015/lisdexamfetamine-dimesylate-a-review-in-paediatric-adhd
#12
James E Frampton
Lisdexamfetamine dimesylate (lisdexamfetamine; Elvanse® ; Tyvense® ), an orally-active dexamfetamine prodrug, is indicated in the EU for the treatment of attention-deficit hyperactivity disorder (ADHD) in children aged ≥ 6 years (including adolescents) when the response to previous methylphenidate (MPH) treatment is clinically inadequate. The original approval of the drug was based on the results of phase III trials in children and adolescents with ADHD who had an inadequate response to previous pharmacotherapy (e...
June 19, 2018: Drugs
https://www.readbyqxmd.com/read/29915898/regorafenib-a-review-in-hepatocellular-carcinoma
#13
Young-A Heo, Yahiya Y Syed
Regorafenib (Stivarga® ), a small molecule inhibitor of multiple kinases, is the first drug to be approved for the treatment of hepatocellular carcinoma (HCC) in patients who have progressed during or after sorafenib therapy. Its approval was based on the results of the randomized, double-blind, placebo-controlled, multinational, phase III RESORCE trial in patients with HCC who had progressed during sorafenib therapy. In RESORCE, regorafenib significantly prolonged overall survival (OS; primary endpoint), progression-free survival (PFS) and time to progression (TTP) compared with placebo, with the OS benefit appearing to be largely due to disease stabilization...
June 18, 2018: Drugs
https://www.readbyqxmd.com/read/29915897/darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-a-review-in-hiv-1-infection
#14
Emma D Deeks
Darunavir/cobicistat/emtricitabine/tenofovir AF (Symtuza® ) is the first protease inhibitor (PI)-based single-tablet regimen (STR) available for the treatment of adults and adolescents (aged ≥ 12 years) with HIV-1 infection. It combines the PI darunavir (which has a high genetic barrier to resistance) with the pharmacokinetic booster cobicistat and the nucleos(t)ide reverse transcriptase inhibitors emtricitabine and tenofovir alafenamide (tenofovir AF), the latter being associated with less off-target tenofovir exposure than its predecessor tenofovir disoproxil fumarate (tenofovir DF)...
June 18, 2018: Drugs
https://www.readbyqxmd.com/read/29915896/targeting-egfr-in-lung-cancer-current-standards-and-developments
#15
REVIEW
Asunción Díaz-Serrano, Pablo Gella, Elisabeth Jiménez, Jon Zugazagoitia, Luis Paz-Ares Rodríguez
Lung cancer is the second most common malignant tumor and the leading cause of cancer death. Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a distinct subtype of lung cancer comprising approximately 15-40% of non-squamous tumors. The development of first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) has been a significant step forward in the treatment of patients with EGFR-mutant tumors, and over the last few years has been the therapy of choice in the initial management of patients with activating mutations in EGFR, with some differences in efficacy and toxicity profile...
June 18, 2018: Drugs
https://www.readbyqxmd.com/read/29915895/the-evolution-of-lung-transplant-immunosuppression
#16
Steven Ivulich, Glen Westall, Michael Dooley, Gregory Snell
Advances in immunosuppression have been a key component to the ongoing success of lung transplantation. The demographics of patients receiving a lung transplant have evolved with older, more critically ill patients and those with previously contraindicated indications, now becoming recipients. Despite the lack of new classes of maintenance immunosuppression drugs becoming available, advances have been made in the prescribing of traditional immunosuppressive therapies. Developments in immunosuppressive regimens have seen changes in the route of administration, approaches to monitoring and combinations used...
June 18, 2018: Drugs
https://www.readbyqxmd.com/read/29766394/treatment-of-eosinophilic-granulomatosis-with-polyangiitis-a-review
#17
Loïc Raffray, Loïc Guillevin
Eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome) is a rare type of anti-neutrophil cytoplasm antibody-associated vasculitis. Nevertheless, eosinophilic granulomatosis with polyangiitis stands apart because it has features of vasculitis and eosinophilic disorders that require targeted therapies somewhat different from those used for other anti-neutrophil cytoplasm antibody-associated vasculitides. Considerable advances have been made in understanding the underlying pathophysiology of eosinophilic granulomatosis with polyangiitis that have highlighted the key role of eosinophils and opened new therapeutic opportunities...
May 15, 2018: Drugs
https://www.readbyqxmd.com/read/29752706/tildrakizumab-first-global-approval
#18
Anthony Markham
Merck & Company Inc. have developed tildrakizumab (tildrakizumab-asmn; Ilumya™), a high-affinity, humanised IgG1 κ monoclonal antibody that specifically targets interleukin-23 p19, as a treatment for chronic plaque psoriasis. The drug was recently approved for marketing by the US FDA based on positive results from the phase III reSURFACE clinical trial programme in patients with chronic plaque psoriasis. This article summarizes the milestones in the development of tildrakizumab leading to this first approval for the treatment of adults with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy...
May 11, 2018: Drugs
https://www.readbyqxmd.com/read/29946963/empagliflozin-a-review-in-type-2-diabetes
#19
James E Frampton
Empagliflozin (Jardiance® ), a potent, highly selective, sodium glucose cotransporter-2 (SGLT2) inhibitor, is an effective and generally well tolerated antihyperglycaemic agent approved for the treatment of adults with type 2 diabetes (T2D) in the EU, USA and Japan, among other parts of the world. As with other members of its class, empagliflozin offers the convenience of once-daily oral administration and carries a low inherent risk of hypoglycaemia as a result of its insulin-independent mechanism of action, enabling it to be used as monotherapy and as a component of combination therapy with other antidiabetic agents with complementary modes of action to improve glycaemic control in patients with T2D...
July 2018: Drugs
https://www.readbyqxmd.com/read/29946962/current-and-emerging-therapeutics-for-the-management-of-endometriosis
#20
REVIEW
Simone Ferrero, Fabio Barra, Umberto Leone Roberti Maggiore
Endometriosis is a chronic benign disease that affects women of reproductive age. Medical therapy is often the first line of management for women with endometriosis in order to ameliorate symptoms or to prevent post-surgical disease recurrence. Currently, there are several medical options for the management of patients with endometriosis. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in the treatment of chronic inflammatory conditions, being efficacious in relieving primary dysmenorrhea. Combined oral contraceptives (COCs) and progestins, available for multiple routes of administration, are effective first-line hormonal options...
July 2018: Drugs
journal
journal
26573
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"